Real-World Safety and Efficacy of Nivolumab in Advanced Squamous and Nonsquamous Non-Small-Cell Lung Cancer: A Retrospective Cohort Study in Croatia, Hungary, and Malta
Table 1
Characteristics of the patients and treatment.
All patients (n = 239)
Tumor histology
Squamous (n = 81)
Nonsquamous (n = 158)
Demographic characteristics
61 (56–66)
62 (58–66)
60 (55–66)
Age at nivolumab initiation (years), median (IQR)
62 (57–68)
64 (60–67)
62 (57–68)
Sex
Female
78 (32.6)
17 (21.0)
61 (38.6)
Male
161 (67.4)
64 (79.0)
97 (61.4)
Clinical characteristics
Stage at introduction of nivolumab
III (unresectable)
10 (4.2)
4 (5.0)
6 (3.8)
IV
228 (95.8)
76 (95.0)
152 (96.2)
Treatment of metastatic disease
Chemotherapy
218 (95.2)
74 (94.9)
144 (95.4)
Tyrosine kinase inhibitors
60 (25.9)
11 (13.9)
49 (32.0)
Metastatic sites
Mediastinal lymph nodes
188 (81.0)
68 (85.0)
120 (78.9)
Lung
181 (78.4)
67 (85.9)
114 (74.5)
Bone
73 (31.9)
18 (23.1)
55 (36.4)
Pleural effusion
60 (26.2)
23 (28.7)
37 (24.8)
Other sites
44 (18.4)
10 (12.3)
34 (21.5)
Brain
39 (16.7)
4 (4.9)
35 (22.9)
Liver
37 (16.0)
13 (16.5)
24 (15.8)
Pleural metastasis
17 (7.4)
2 (2.5)
15 (10.0)
Abdominal lymph nodes
17 (7.4)
5 (6.3)
12 (8.0)
Number of metastatic sites, median (IQR)
3 (2–4)
2 (2–3)
3 (2–4)
ECOG performance status
0
125 (52.3)
43 (53.1)
82 (51.9)
1
110 (46.0)
37 (45.7)
73 (46.2)
≥2
4 (1.7)
1 (1.2)
3 (1.9)
EGFR status positive (among those tested)
15/145 (10.3)
0/5 (0.0)
15/140 (10.7)
ALK rearrangements present (among those tested)
2/116 (1.7)
0/2 (0.0)
2/114 (1.8)
Time from diagnosis to introduction of nivolumab (months), median (IQR)
18 (11–30)
16 (11–26)
19 (11–31)
Number of cycles, median (IQR)
12 (4–28)
13 (5–25)
11 (4–29)
Treatment duration (months), median (IQR)
5 (2–12)
6 (2–11)
5 (2–15)
Therapy after nivolumab
83 (35.8)
29 (35.8)
54 (35.8)
Data are presented as the number (percentage) of patients if not stated otherwise. Abbreviations: IQR = interquartile range; EGFR = epidermal growth factor receptor; ALK = anaplastic lymphoma kinase.
